### YaleNewHaven**Health**

**Smilow Cancer Hospital** 



A Comprehensive Cancer Center Designated by the National Cancer Institute

# **Grand Rounds**

## Friday, May 3, 9:00am **Richard Frisbee III Memorial Lectureship**

#### **Cell Therapies for Blood Cancers-Beyond Conventional CAR-T**



Catherine Bollard, MBChB, MD
Dr. Robert J. and Florence T. Bosworth Distinguished Professor of Cancer and Transplantation Biology Research; Interim Executive Vice President & Chief Academic Officer, Children's National Hospital/Children's National Research Institute; Interim Chair, Department of Pediatrics; Associate Dean, Pediatric Academic Affairs; Director, Center for Cancer and Immunology Research, Children's National Hospital The George **Washington University School of Medicine and Health Sciences** 


#### 55 Park Street Auditorium I Zoom Access Continental breakfast will be available

Needs: Rapid advances in the field of hematopoietic cell transplantation (HCT), as well as the advent of immune effector cell therapy (IEC), have resulted in an increasing number of patients undergoing these therapies and an increasing level of expertise required to manage them.

Objectives: To explain the difference between CAR-T and antigen-specific T cells. Evaluate the applicability's for off the shelf cell therapies. Illustrate the safety and potency of different cell therapies for leukemias and lymphomas beyond conventional CAR-T.







Dr. Catherine Bollard leads clinical and research efforts to fight cancer and other inflammatory diseases by strengthening the immune system using adoptive cell therapy. As a past president of the International Society of Cellular Therapy, and the current president of the Foundation for the Accreditation for Cellular Therapy (FACT), she is a distinguished hematologist, immunologist, and immunotherapist, working to develop cell and gene therapies for patients with cancer and underlying immune deficiencies.

Additionally, Dr. Bollard is interested in stem cell and cord blood transplantation and improving outcomes by decreasing infectious complications and preventing relapse. She also has a specific interest in targeting viral infections in immune-suppressed patient populations, including individuals living with the human immunodeficiency virus. As a national and international leader in the immunology and immunotherapy space, Dr. Bollard's work expands our understanding of cancer, immune deficiencies, and viral infections in pediatric and adult patients.

There is No Corporate Support for These Activities. Accreditation: The Yale School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Designation Statement: The Yale School of Medicine designates this live activity for 1 AMA PRA Category 1 Credit(s)<sup>TM</sup>. Physicians should only claim credit commensurate with the extent of their participation in the activity. Target Audience: YCC members, Smilow faculty, YSM, Nursing, Public Health Students. Faculty Disclosures: Winer- nothing to disclose. Bollard- Neximmune - stock holder | Repertoire Immune Medicines - stock holder | Mana Therapeutics - Past Co-founder and SAB member with stock options. Catamaran Bio - Past Co-founder and SAB member with stock options. Minovia TX Ltd - SAB member with stock options. Minovia TX Ltd - SAB member with stock options of Financial Relationships Statement: Yale CME adheres to the ACCME's Standards for Integrity and Independence in Accredited Continuing Medical Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the

commencement of the activity.